Adjuvant interferon-alpha for melanoma revisited: News from old and new studies

Annals of Oncology

Volumn 12, Issue 12, 2001, Pages 1663-1666

  Punt, C J A ^a   Eggermont, A M M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant therapy; Interferon alfa; Melanoma; Review low dose IFN trials

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; GAMMA INTERFERON; GANGLIOSIDE GM2; QS 21; VISCUM ALBUM EXTRACT;

CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; MELANOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; INTERFERON-ALPHA; MELANOMA; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035700212     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013592219007     Document Type: Review

References (15)

1. A new American Joint Committee on Cancer Staging system for cutaneous melanoma
2. The AJCC staging proposal for cutaneous melanoma: Comments by the EORTC Melanoma Group
3. Adjuvant interferon alpha in high risk melanoma: The Scottish study
4. Adjuvant interferon α-2a treatment in resected primary stage II cutaneous melanoma
5. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
6. Aim highadjuvant interferon in melanoma (high risk), a United Kingdom Co-ordinating Committee on Cancer Research (IKCCCR) randomised study of observation vs. adjuvant low dose extended duration interferon alfa-2a in resected malignant melanoma
7. Effect of long-term adjuvant therapy with interferon-alpha2a in patients with regional node metastases from cutaneous melanoma: A randomized trial
8. Results of adjuvant interferon study in WHO melanoma programme
9. High- and lowdose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
10. The European Organization for Research and Treatment of Cancer Melanoma Group Trial experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon alpha-2b
11. Interferon-α2b adjuvant therapy of high-risk resected curaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
12. Randomized surgical adjuvant clinical trial or recombinant interferon-alfa-2a in selected patients with malignant melanoma
13. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
14. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter ECOG phase II trial E 2696
15. Pooled analysis of four ECOG-Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma